⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685342 | 0.97 | — | — | |
| SCHEMBL1538500 | 0.83 | TDP1 (0.52) | — | |
| Dianhydrogalactitol SCHEMBL4304281 | 0.83 | THRB (0.30) | — | |
| Dianhydrogalactitol SCHEMBL17264073 | 0.83 | THRB (0.30) | — | |
| Dianhydrogalactitol SCHEMBL15496475 | 0.83 | THRB (0.30) | — | |
| Dianhydrogalactitol SCHEMBL4307933 | 0.83 | THRB (0.30) | — | |
| Dianhydrogalactitol SCHEMBL4306431 | 0.83 | THRB (0.30) | — | |
| Dianhydrogalactitol SCHEMBL16387832 | 0.83 | THRB (0.30) | — | |
| Dianhydrogalactitol SCHEMBL8375579 | 0.83 | THRB (0.30) | — | |
| Dianhydrogalactitol SCHEMBL4304284 | 0.83 | THRB (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| CN-119735613-A | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 武田药品工业株式会社 | 2025-04-01 | — | — | CN | disclosed |
| EP-2300013-B2 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-13 | — | — | EP | disclosed |
| US-20240299363-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2024-09-12 | — | — | US | disclosed |
| US-12011432-B2 | Method of modulating ribonucleotide reductase | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20240043457-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4[(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-08 | — | — | US | disclosed |
| US-20230321177-A1 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | AVETA BIOMICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3773654-B1 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | AVETA BIOMICS INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230172911-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ARIAD PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230016609-A1 | MESOPOROUS SILICA NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-19 | — | — | US | disclosed |
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-11439623-B2 | Method of modulating ribonucleotide reductase | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-09-13 | — | — | US | disclosed |
| US-11427605-B2 | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2022-08-30 | — | — | US | disclosed |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | UNIVERSITY OF WASHINGTON (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220079923-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2022-03-17 | — | — | US | disclosed |
| US-11260127-B2 | Mesoporous silica nanoparticles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |